Related posts

Nervous markets await Nvidia
Investor Insights

This summary was created by AI, based on 4 opinions in the last 12 months.

Knight Therapeutics (GUD-T) has garnered attention from several analysts, highlighting its potential as a solid long-term hold, particularly on pullbacks. Despite recent volatility in Latin American markets, experts believe the company’s strong cash position and capital discipline will allow it to leverage acquisitions effectively. Some reviews emphasize the hidden gem status of Knight Therapeutics, with a strong topline growth and margin expansion potential driven by its acquisition strategy. However, while the stock is up significantly year-to-date, recent earnings showed mixed results, with some contributors noting that challenges remain despite a promising net cash position. Overall, analyses suggest a cautious optimism, advocating for patience as the company works towards improving margins over time.

Consensus
Hold
Valuation
Undervalued
PAST TOP PICK
(A Top Pick Sep 10/24, Up 3%)

Solid hold over the longer term, need patience. Accumulate on any pullback. Volatility of Latin American markets is not helping, so watch that. Understands how to monetize recent acquisition.

PAST TOP PICK
(A Top Pick Sep 10/24, Down 11%)

(Note the short timeframe.)
One of the cheapest small caps, accumulate on weakness. Pullback gives you the opportunity. Good job setting stage for margin improvement over time, not overnight. High net-cash position. Capital discipline, good insider ownership. 

TOP PICK

A hidden gem. Low liquidity, but has good topline growth, strong margin expansion potential and the CEO has a great track record from Paladin Labs. It buys existing drug platforms, and can now leverage that platform to introduce new drug therapies. Huge net cash and keep buying back shares. 

(Analysts’ price target is $7.60)
DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

The stock is acting better, and is up 15% YTD. It has been a while since it saw $6. EPS was -4c vs expectations of (nil). Revenue was $86.6M, beating estimates of $83.1M. EBITDA of $13.58M missed estimates of this $14.47M. Guidance was largely maintained. Revenue rose 4.9%, with margins a bit higher than estimates. Net cash is about $90M. Still not much excitement here. Some recent partnerships look more interesting than the quarterly results. It is good to see the sales gain, but we would not yet call this a dramatic turn. 
Unlock Premium - Try 5i Free

DON'T BUY

Years ago, they bought a major company that he owned a lot of shares in. He's waiting for another such purchase by GUD before considering it. He's looking for companies with growth and earnings.

HOLD

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free

HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. I Good Q2 results but weaker bottom line. Growth potential remains. No dividend to keep investors patient. Valuation arguably more attractive today.
BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable.
HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Rating maintained at ‘B'.
HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Sales 30% ahead of estimates. M&A pipeline active, investors expect more. COVID helped sales growth. Impressive quarter results.
WAIT
The superstar CEO with a great track record raised a pile of cash, but didn't do anything with it. He had a short position on this 6 months ago, and covered that recently. GUD has poor price momentum, though little volatility, and no real earnings. PE is high, though a strong balance sheet. This is a show-me story.
HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Although the stock has not moved, the basic thesis has not changed. There is some weakness in South America which has impacted their acquisition. With no dividend, there is an opportunity cost to the stock, but outlook remains intact. Unlock Premium - Try 5i Free

WEAK BUY
The CEO has a great track record, but he's been slow to deploy capital which the market doesn't like. He bought a company in Brazil, so there's currency risk. Hold on and be patient. Short-term, investors are frustrated, but long term this should be fine. The CEO is sitting on a lot of cash.
BUY

Brilliant CEO. It's sitting on a lot of cash, because of the CEO who is patient and will slowly build Knight. He's not chasing acquisitions to spend cash.

HOLD
A frustrating name. They have a great management team. For a couple of years, he has been waiting for the execution of a big deal that finally came about. The market is selling it down and he is not really sure why. He thinks investors are just selling it off with the uncertainty in the market currently. It trades at 0.7 times book value. He still thinks things are fine.
Showing 1 to 15 of 103 entries

Knight Therapeutics(GUD-T) Rating

Ranking : 3 out of 5

Star iconStar iconStar iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Knight Therapeutics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Knight Therapeutics(GUD-T) Frequently Asked Questions

What is Knight Therapeutics stock symbol?

Knight Therapeutics is a Canadian stock, trading under the symbol GUD-T on the Toronto Stock Exchange (GUD-CT). It is usually referred to as TSX:GUD or GUD-T

Is Knight Therapeutics a buy or a sell?

In the last year, 3 stock analysts published opinions about GUD-T. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Knight Therapeutics.

Is Knight Therapeutics a good investment or a top pick?

Knight Therapeutics was recommended as a Top Pick by on . Read the latest stock experts ratings for Knight Therapeutics.

Why is Knight Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Knight Therapeutics worth watching?

3 stock analysts on Stockchase covered Knight Therapeutics In the last year. It is a trending stock that is worth watching.

What is Knight Therapeutics stock price?

On 2025-04-25, Knight Therapeutics (GUD-T) stock closed at a price of $5.9.